AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02359968
Drug: CarboP-pacliT
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: radiochemotherapy before surgery
Trial: NCT03602066
Drug: Chlorine Dioxide Sterilization
DrugBank: Chlorine (DB11109)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given via oral rinse
Trial: NCT03371550
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy
Trial: NCT03371550
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy
Trial: NCT02449044
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once Daily
Trial: NCT04207255
Drug: Opaganib
RxNorm normalized name: Opaganib
DrugBank: Opaganib (DB12764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg of Opaganib orally twice a day continuously.
Trial: NCT04207255
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV as directed by SOC
Trial: NCT04207255
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV as directed by SOC
Trial: NCT04207255
Drug: Opaganib
RxNorm normalized name: Opaganib
DrugBank: Opaganib (DB12764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg of Opaganib orally twice a day continuously.
Trial: NCT02961842
Drug: 500 mL Colloid Preload
RxNorm normalized name: Colloidal silica
DrugBank: Silicon dioxide (DB11132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 500 mL will be rapidly infused before spinal anesthesia
Trial: NCT02961842
Drug: Intrathecal Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
Trial: NCT02961842
Drug: Intravenous Ephedrine
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
Trial: NCT01620424
Drug: biphasic insulin aspart 30
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
Trial: NCT01620424
Drug: biphasic insulin aspart 50
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
Trial: NCT01366391
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500 mg tablet (1000 or 1500 mg/day)
Trial: NCT00806065
Drug: ENMD-2076
RxNorm normalized name: ENMD-2076 free base
DrugBank: ENMD-981693 (DB16891)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03563222
Drug: Smoflipid
RxNorm normalized name: Smoflipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study drugs will be infused via a dedicated line for parenteral nutrition (PN) into a central vein using a central venous catheter or a peripherally inserted central catheter.~The initial rate of infusion should be no more than 0.05 mL/minute for the first 10 to 15 minutes. If no untoward reactions occur, the rate can be changed to permit infusion of 0.5 mL/kg/hour.~The individual dosage of study drug should be infused at a constant rate for 10 to 24 h/d. The administration flow rate is determined by dividing the volume of study drug by the duration of the infusion. Maximum infusion rate for lipid should not exceed 0.125 g/kg/h lipid.~Study drug infusions should be given 5 to 7 days per week. Study treatment will last for a minimum of 90 consecutive days and as long as PN is indicated, up to 365 consecutive days. If the indication for PN continues after Study Day 365, PN will continue per normal institution policy.
Trial: NCT01197833
Drug: endovenous ablation+polidocanol injectable microfoam 0.125%
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All components except API
Trial: NCT01197833
Drug: Endovenous ablation+polidocanol injectable microfoam 1.0%
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%
Trial: NCT03845894
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interscalene brachial plexus blockade using liposomal bupivacaine (expanded with plain bupivacaine)
Trial: NCT03845894
Drug: Bupivacaine with adjuvants
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interscalene brachial plexus blockade using plain bupivacaine with adjuvants: clonidine, epinephrine, buprenorphine, dexamethasone.
Trial: NCT03082742
Drug: Hydrochlorothiazide
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03082742
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02791373
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mobilisation Chemotherapy
Trial: NCT03496740
Drug: Bupivacaine (Block Drug)
RxNorm normalized name: bupivacaine Drug Implant
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Block drug
Trial: NCT03736967
Drug: REGN3500
RxNorm normalized name: Immunoglobulin igg4 (230-proline), anti-(human interleukin 33) (human monoclonal regn3500 .gamma.4-chain), disulfide with human monoclonal regn3500 .kappa.-chain, dimer
DrugBank: Itepekimab (DB16206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneous (SC) every 2 weeks (q2w)
Trial: NCT03736967
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC q2w
Trial: NCT03736967
Drug: REGN3500 + Dupilumab Combo
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered SC q2w
Trial: NCT02791373
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mobilisation Chemotherapy
Trial: NCT04556461
Drug: Tralokinumab
RxNorm normalized name: tralokinumab
DrugBank: Tralokinumab (DB12169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2 x 300 mg Tralokinumab s.c. loading dose followed by 8 x 300 mg every 2 weeks (Q2W)
Trial: NCT01593306
Drug: Paclitaxel, Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous paclitaxel infusion at 50mg/m2/week and cisplatin at 30mg/m2/week for 5 weeks. if supplement Chemo Radiotherapy is required then similar dose per week for 2 more weeks.
Trial: NCT01593306
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusion of cisplatin 40mg/m2/week for 5 weeks. if I/C Brachytherapy is not feasible then supplement CRT given with similar dose of cisplatin for 2 more cycles.
Trial: NCT01939054
Drug: Nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01939054
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00879190
Drug: Unasyn
RxNorm normalized name: Unasyn
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
Trial: NCT02882113
Drug: Advagraf
RxNorm normalized name: Astagraf
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: same dose as Tacrolimus bid der day in 24 weeks
Trial: NCT00135759
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: low dose naltrexone in addition to daily methadone taper
Trial: NCT00135759
Drug: naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.125 mg capsule/day for 6 days
Trial: NCT00135759
Drug: naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.250 mg capsule/day for 6 days
Trial: NCT01539304
Drug: CITUS Dry Syrup
RxNorm normalized name: Felis catus skin
DrugBank: Felis catus skin (DB10399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pranlukast 10% dry syrup, b.i.d.
Trial: NCT02634346
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily dosing
Trial: NCT00605644
Drug: MOA-728
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral Capsules
Trial: NCT01246752
Drug: Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5
Trial: NCT00167817
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00802425
Drug: AM-111
RxNorm normalized name: MM-111
DrugBank: MM-111 (DB17983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single intratympanic injection
Trial: NCT01749605
Drug: Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days
DrugBank: Nitrofurantoin (DB00698)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01749605
Drug: ciprofloxacin 250 mg BID x 3 days
RxNorm normalized name: ciprofloxacin 250 MG
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00348231
Drug: dual-action insulin analog
RxNorm normalized name: Tums Dual Action
DrugBank: Famotidine (DB00927)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04372407
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib: 200 mg as single dose on Days 1 and 9
Trial: NCT04372407
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole: 200 mg BID on Day 5, then 200 mg QD on Days 6 to 14
Trial: NCT00437580
Drug: Lactobacillus casei rhamnosus (strain Lcr 35 LC)
RxNorm normalized name: Lactobacillus casei rhamnosus
DrugBank: Lactobacillus casei (DB16541)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic or to a 5 weeks regimen with placebo.
Trial: NCT00193635
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral drug administration
Trial: NCT02075268
Drug: prasugrel
RxNorm normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
Trial: NCT03486457
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablets, 5 mg BID x 6 months
Trial: NCT03486457
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablets, 5 mg BID x 3 months
Trial: NCT04446533
Drug: Hydrogen Peroxide and Hyaluronic acid filming formulation
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with BMG0703 by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of BMG0703 will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth).
Trial: NCT04446533
Drug: Chlorhexidine 0.2%
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will undergo a professional oral hygiene session (causal therapy) and will be instructed to perform proper oral hygiene manoeuvres at home.~After the causal therapy, the treatment of the pockets will be performed by probing, between 3 and 7 mm, with Chlorhexidine 0.2% by means of a dedicated sterile syringe. The application will be repeated after approx. 5 minutes.~One bottle of Chlorhexidine 0.2% will then be given to the patients who will be instructed to use it 3 times a day, after meals and after normal oral hygiene procedures, for at least one week.~The subjects will then be re-evaluated after 3 days and after a week. During these check-ups, new samples will be collected at the level of the initial sampling sites and will be reassessed on the basis of the selected clinical indices (in particular plaque, bleeding and probing depth).
Trial: NCT03853798
Drug: AG-348
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 5, 20, or 50 mg twice a day for up to 192 weeks (not including dose taper) unless the dose is modified for reasons related to safety.
Trial: NCT02573220
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01174160
Drug: vernakalant hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Vernakalant (DB06217)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.
Trial: NCT01174160
Drug: Placebo to vernakalent hydrochloride
DrugBank: Kale (DB14564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
Trial: NCT00212628
Drug: Minodronic acid hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Minodronic acid (DB06548)
FDA approved: no
EMA approved: no
PMDA approved: yes
Trial: NCT01458587
Drug: Vehicle PDT (VEH)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
Trial: NCT00304629
Drug: galantamine
RxNorm normalized name: Galantamine
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00388999
Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
RxNorm normalized name: Recombinant human mannose-binding lectin
DrugBank: Mannose (DB12907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
Trial: NCT03056053
Drug: Zolpidem
RxNorm normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercially available tablets of zolpidem (5 or 10 mg) for oral use
Trial: NCT00778050
Drug: Amoxicillin 600mg
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03126708
Drug: cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: cetuximab (EGFR monoclonal antibody) plus standard chemotherapy
Trial: NCT03126708
Drug: cisplatin plus paclitaxel
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT03157089
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Film-coated tablet
Trial: NCT03157089
Drug: pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Solution for infusion
Trial: NCT00255385
Drug: Micronutrient (Zinc and Iron) fortification
RxNorm normalized name: iron and multivitamins
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00255385
Drug: Pre and Probiotic fortification
RxNorm normalized name: Rezyst Probiotic
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02453607
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
Trial: NCT00977197
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
Trial: NCT04176913
Drug: LUCAR-20S CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An Anti-CD20 Allogeneic CAR-T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell, Follicular, Mantle Cell or Small Lymphocytic Lymphoma
Trial: NCT03758469
Drug: rifampin , HSK3486
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequence 2: Orally take 600 mg rifampin once a day for 8 consecutive days in the morning on an empty stomach, followed by 1 min intravenous infusion of 0.4 mg/kg HSK3486 30 min later.
Trial: NCT02025075
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
Trial: NCT00546442
Drug: Metformine
RxNorm normalized name: Metformine
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 850-2550 mg/daily for 48 weeks
Trial: NCT02419872
Drug: Marketed antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Medication for each patient is determined by the physician based on the patient's individual clinical profile and in accordance with the approved indication and label of the prescribed drug
Trial: NCT03248037
Drug: Netarsudil
RxNorm normalized name: NETARSUDIL
DrugBank: Netarsudil (DB13931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: netarsudil opthalmic solution 0.02%
Trial: NCT04259970
Drug: Initiation of CFTR Modulator
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled contrast for MRI occurring at each 4 visits.
Trial: NCT01169805
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron/single injection/4 mg/IV
Trial: NCT01169805
Drug: Ramosetron
RxNorm normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Ramosetron HCl/single injection/0.3mg/IV
Trial: NCT01169805
Drug: Palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Palonosetron HCl/single injection/0.075mg/IV
Trial: NCT01483118
Drug: Cinnamon Extract
RxNorm normalized name: Cinnamon Extract
DrugBank: Chinese cinnamon (DB16593)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified aqueous abstract of cinnamon in 125mg capsules, which would be taken orally before each meal, for a total of 1,500mg/day for 6 months.
Trial: NCT02791256
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02791256
Drug: peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03720119
Drug: Lidocaine Hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: As per clinical practice, a local treatment with ORTODERMINA® over a 14-day period (once a day) was prescribed. ORTODERMINA® contains 5% of lidocaine hydrochloride.